Blue Chip Venture Company

About The Fund

Founded in 1990 and based in Cincinnati, Ohio, Blue Chip Venture Company is a venture capital firm that specializes in investing in a diversified portfolio of industries, including healthcare, marketing and media services, software, and services. The firm targets early and growth-stage companies, dedicating approximately half of its capital to ventures located in the Midwest. Blue Chip Venture Company is distinguished by its strategy of participating in the last financing rounds, which are usually aimed at strengthening the company's balance sheet in preparation for an imminent liquidity event, such as an IPO or acquisition. On average, the firm invests $1 to $4 million per company with a minimum investment threshold of $1 million and a maximum of $70 million. Blue Chip manages assets worth $600 million and has an expansive investment reach, with over 170 companies in its portfolio across the United States. Blue Chip Venture Company's expertise includes equity and mezzanine investments, catering to various specialist areas like early-stage ventures, expansion phases, management buyouts/leveraged buyouts (MBO/LBO), and acquisitions. Their achievements include successful exits through initial public offerings for companies such as LifeLock and Endocyte, as well as the sales of BioVex and Nexsan. The firm's Blue Chip V and Blue Chip VI funds have continued this investment strategy, with the former closing in May 2012 and achieving 15 investments and several exits within two years. The latter closed in June 2013, perpetuating the firm's tradition of supporting businesses on their path to significant financial events.